REGENERIX LLC

Tucson, AZ · Biotech · Private

Small-molecule inhibitors targeting the RIPK3-MLKL protein-protein interface to block necroptosis and treat Alzheimer's disease

Grants
$450K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Targeting Necroptosis for Neurodegenerative Disease Therapy$449,594
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1584Stem Biotech LLC—$100M
1585BeneFix, Inc.—$8.6M
1586H-CYTE, INC.—$11M
1587REGENERIX LLC——
1588CHEMILY, LLC——
1589REGENTIS BIOMATERIALS LTD.—$6.5M
1590LEXEO Therapeutics LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.